Moderna Inc. (NASDAQ:MRNA) trade information

Instantly MRNA was in red as seen at the end of in last trading. With action -1.57%, the performance over the past five days has been red. The drop to weekly highs of 115.25 on Monday, 09/18/23 subtracted -9.12% to the stock’s daily price. The company’s shares are showing year-to-date downside of -42.02%, with the 5-day performance at -1.57% in the red. However, in the 30-day time frame, Moderna Inc. (NASDAQ:MRNA) is -1.98% down. Looking at the short shares, we see there were 18.05 million shares sold at short interest cover period of 4.06 days.

The consensus price target for the stock as assigned by Wall Street analysts is $179.31, meaning bulls need an upside of 41.92% from its current market value. According to analyst projections, MRNA’s forecast low is $66.00 with $430.00 as the target high. To hit the forecast high, the stock’s price needs a -312.91% plunge from its current level, while the stock would need to tank 36.62% for it to hit the projected low.

Moderna Inc. (MRNA) estimates and forecasts

Data shows that the Moderna Inc. share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -30.58% over the past 6 months, a -121.47% in annual growth rate that is considerably lower than the industry average of 11.90%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Moderna Inc. will fall -162.50%, while the growth in revenue is estimated to hit -59.30% for the next quarter. Year-over-year growth is forecast to reach -62.90% down from the last financial year.

Consensus estimates given by 13 financial analysts project the company’s revenue in the current quarter to hit an average of $1.6 billion. 13 analysts are of the opinion that Moderna Inc.’s revenue for the quarter ending Dec 2023 will be $3.44 billion. The company’s revenue for the corresponding quarters a year ago was $3.36 billion and $5.08 billion respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -52.40%. The estimates for the next quarter sales put growth at -32.30%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 92.10%. The 2023 estimates are for Moderna Inc. earnings to decrease by -29.00%.

MRNA Dividends

Moderna Inc. is expected to release its next quarterly earnings report between November 01 and November 06.

Moderna Inc. (NASDAQ:MRNA)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 9.69% of Moderna Inc. shares while 69.48% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 76.93%. There are 69.48% institutions holding the Moderna Inc. stock share, with Baillie Gifford and Company the top institutional holder. As of Jun 29, 2023, the company held 12.01% of the shares, roughly 45.71 million MRNA shares worth $5.55 billion.

Vanguard Group Inc holds the second largest percentage of outstanding shares, with 7.22% or 27.46 million shares worth $3.34 billion as of Jun 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Vanguard International Growth Fund. With 10.11 million shares estimated at $1.23 billion under it, the former controlled 2.66% of total outstanding shares. On the other hand, Vanguard International Growth Fund held about 2.47% of the shares, roughly 9.42 million shares worth around $1.2 billion.